In Many Regions, World Tuberculosis Day is Every Day

Post Date: 

India Assumes the Greatest Burden

Each year on March 24, the world pauses to reflect on the devastation that tuberculosis causes globally. TB is preventable and treatable, and it disproportionately and gravely affects resource-limited regions of the world. The World Health Organization reports that TB is a top killer globally, and that upwards of 95% of TB-related deaths are among people in low and middle income countries. Moreover, it ranks in the top five causes of death among women aged 15-44 years.[1]

India leads the world in TB-related illness and death globally. And that’s why TB prevention and treatment is our charge every day at CCGHE. Through our clinical research partnerships in India, we are determined to identify new therapies and care strategies that reduce the impact of TB. Our studies are looking to:  

  • Find the triggers that signal progression from latent TB to active TB
  • Link patients to care swiftly
  • Ensure that patients with active TB stay in care
  • Prevent mother-to-child transmission of TB
  • Ensure that global health workers and medical trainees are adequately trained and protected
  • Establish robust data and specimen collections that are globally linked to further the science on TB

Through NIH-funded clinical trials, and through the broad array of clinical research and education efforts noted below, we intend to knock the wind out of TB. You can join us by supporting our efforts.



  1. ACTG 5274: Phase IV, Open Label Strategy Trial: REMEMBER: Reducing Early Mortality and Early Morbidity by Empiric TB Treatment Regimens
  2. ACTG 5279: Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-infected Individuals with Latent Tuberculosis Infection
  3. ACTG 5300/IMPAACT 2003: Phase III, Open Label, Multi-center Trial: Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant TB Patients
  4. IMPAACT 1077B/1077FF: Promoting Maternal and Infant Survival Everywhere (PROMISE): Breastfeeding and Formula Feeding Versions
  5. IMPAACT 1078: Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High TB Incidence Settings
  6. IMPAACT 1108: A Phase I/II, Open-label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination with Optimized Individualized Multidrug-resistant Tuberculosis (MDR-TB) Therapy in HIV-infected and Uninfected Infants, Children, and Adolescents with MDR-TB Disease
  7. IMPAACT 2005: A Phase I/II Open-label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in Children with MDR-TB and HIV Co-Infection
  8. Analysis of Data Collected from the Evaluation of Community-Based Education, Research and Service (COBERS) Medical Education Partnership
  9. ART Study 1: Database: Epidemiology of HIV/AIDS and Associated Comorbidities in a Public Antiretroviral Treatment (ART) Clinic at BJGMC in Pune
  10. Assessing the Association of Indoor Air Pollution with TB in Adult Women and Children under 5 Years of Age
  11. Barriers for Intervention to Prevent Occupationally Acquired TB in HCWs
  12. Diagnosis of TB Infection and Th1 Immune Response in Pregnant Women in India
  13. Hair Concentrations of Anti-TB Drugs Among HIV-Infected and Uninfected Children in India
  14. Impact of Diabetes on TB Treatment Outcomes: TB-Diabetes Cohort
  15. Impact of Malnutrition on HIV Treatment Failure in Resource-Limited Settings
  16. MDR- TB South Africa: Patient Linkage to and Retention in Care
  17. MiDOT (Directly Observed Therapy) Mobile Health Pilot Study
  18. Optimizing Treatment to Improve TBM Outcomes in Children
  19. A Phase I/II Randomized, Open-label Trial to Evaluate the Pharmacokinetics, Safety, and Treatment Outcomes of Multidrug Treatment Including High Dose Rifampicin with or without Levofloxacin versus Standard Treatment for Pediatric Tuberculous Meningitis  
  20. Predictive Value of TB-Symptom Screen in HIV-infected and HIV-uninfected Pregnant Women in Pune, India
  21. Predictive Value of TB-Symptom Screen in HIV-infected and HIV-uninfected Pregnant Women in Pune, India: Substudy: Studying the Molecular Mechanisms Leading to Suppressed Immunity in Pregnancy and Studying the Relationship between Diet, Gut Microbiome, and Inflammation during Pregnancy  
  22. RePORT India: Common Protocol
  23. RePORT India: Common Protocol: Comparison of Available Purified-Protein Derivative (PPD) TB Skin Test (TST) Antigen Solutions in Detecting Latent TB Infection in India (
  24. RePORT India: c-TRIUMPH: Parent Protocol: Cohort for TB Research by the Indo-US Medical Partnership
  25. RePORT India: c-TRIUMPH: Cohort for TB Research by the Indo-US Medical Partnership: Substudy on Residual Respiratory Impairment Following Pulmonary TB  
  26. RePORT: c-TRIUMPH: Understanding of TB Infection and Preventive Therapy among Skin-Test Positive Household Contacts of TB Cases
  27. Risk of TB among Health Care Workers and Trainees in a Tertiary-care Hospital in Pune, India
  28. Shorter Treatment for Minimal TB in Children. A Randomized Trial of Therapy Shortening for Minimal Tuberculosis with New WHO-recommended Doses/Fixed-dose-combination Drugs in African and Indian HIV+ and HIV- Children
  29. TB and Pregnancy: Impact of Immune Changes HIV and Stages of Pregnancy on Tuberculosis  
  30. TB Live Case Discussion
  31. TB Live Noon Conference



  1. Tuberculosis fact sheet. World Health Organization website. Updated October 2015. Accessed March 1, 2016.